194 related articles for article (PubMed ID: 27094132)
1. Progress in drug development for Alzheimer's disease: An overview in relation to mitochondrial energy metabolism.
Hroudová J; Singh N; Fišar Z; Ghosh KK
Eur J Med Chem; 2016 Oct; 121():774-784. PubMed ID: 27094132
[TBL] [Abstract][Full Text] [Related]
2. Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission.
Korábečný J; Nepovimová E; Cikánková T; Špilovská K; Vašková L; Mezeiová E; Kuča K; Hroudová J
Neuroscience; 2018 Feb; 370():191-206. PubMed ID: 28673719
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity.
Singh N; Hroudová J; Fišar Z
Mol Neurobiol; 2017 Oct; 54(8):5894-5904. PubMed ID: 27660276
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Bautista-Aguilera OM; Esteban G; Bolea I; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Samadi A; Soriano E; Unzeta M; Marco-Contelles J
Eur J Med Chem; 2014 Mar; 75():82-95. PubMed ID: 24530494
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer's disease.
Li F; Wang ZM; Wu JJ; Wang J; Xie SS; Lan JS; Xu W; Kong LY; Wang XB
J Enzyme Inhib Med Chem; 2016; 31(sup3):41-53. PubMed ID: 27384289
[TBL] [Abstract][Full Text] [Related]
6. Effects of Novel Tacrine Derivatives on Mitochondrial Energy Metabolism and Monoamine Oxidase Activity-In Vitro Study.
Hroudová J; Nováková T; Korábečný J; Maliňák D; Górecki L; Fišar Z
Mol Neurobiol; 2021 Mar; 58(3):1102-1113. PubMed ID: 33089424
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases.
Mathew B; Parambi DGT; Mathew GE; Uddin MS; Inasu ST; Kim H; Marathakam A; Unnikrishnan MK; Carradori S
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900177. PubMed ID: 31478569
[TBL] [Abstract][Full Text] [Related]
8. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
Samadi A; de los Ríos C; Bolea I; Chioua M; Iriepa I; Moraleda I; Bartolini M; Andrisano V; Gálvez E; Valderas C; Unzeta M; Marco-Contelles J
Eur J Med Chem; 2012 Jun; 52():251-62. PubMed ID: 22503231
[TBL] [Abstract][Full Text] [Related]
9. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
Wang L; Esteban G; Ojima M; Bautista-Aguilera OM; Inokuchi T; Moraleda I; Iriepa I; Samadi A; Youdim MB; Romero A; Soriano E; Herrero R; Fernández Fernández AP; Ricardo-Martínez-Murillo ; Marco-Contelles J; Unzeta M
Eur J Med Chem; 2014 Jun; 80():543-61. PubMed ID: 24813882
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
Manzoor S; Hoda N
Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Bolea I; Juárez-Jiménez J; de Los Ríos C; Chioua M; Pouplana R; Luque FJ; Unzeta M; Marco-Contelles J; Samadi A
J Med Chem; 2011 Dec; 54(24):8251-70. PubMed ID: 22023459
[TBL] [Abstract][Full Text] [Related]
12. Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives.
Wang Y; Sun Y; Guo Y; Wang Z; Huang L; Li X
J Enzyme Inhib Med Chem; 2016; 31(3):389-97. PubMed ID: 25798687
[TBL] [Abstract][Full Text] [Related]
13. DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Qiang X; Li Y; Yang X; Luo L; Xu R; Zheng Y; Cao Z; Tan Z; Deng Y
Bioorg Med Chem Lett; 2017 Feb; 27(4):718-722. PubMed ID: 28131710
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease.
Knez D; Sova M; Košak U; Gobec S
Future Med Chem; 2017 May; 9(8):811-832. PubMed ID: 28504893
[TBL] [Abstract][Full Text] [Related]
15. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Sun Y; Chen J; Chen X; Huang L; Li X
Bioorg Med Chem; 2013 Dec; 21(23):7406-17. PubMed ID: 24128814
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Yang HL; Cai P; Liu QH; Yang XL; Li F; Wang J; Wu JJ; Wang XB; Kong LY
Eur J Med Chem; 2017 Sep; 138():715-728. PubMed ID: 28728104
[TBL] [Abstract][Full Text] [Related]
18. Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
Behl T; Kaur D; Sehgal A; Singh S; Sharma N; Zengin G; Andronie-Cioara FL; Toma MM; Bungau S; Bumbu AG
Molecules; 2021 Jun; 26(12):. PubMed ID: 34207264
[TBL] [Abstract][Full Text] [Related]
19. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
Joubert J; Foka GB; Repsold BP; Oliver DW; Kapp E; Malan SF
Eur J Med Chem; 2017 Jan; 125():853-864. PubMed ID: 27744252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
